Utilización combinada de fármacos para la prevención cardiovascular: más allá de una polipastilla

Wald, 2003, A strategy to reduce cardiovascular disease by more than 80%, BMJ, 326, 1419, 10.1136/bmj.326.7404.1419 Ridker, 2005, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women, N Engl J Med, 352, 1293, 10.1056/NEJMoa050613 Law, 2002, The underlying risk of death after myocardial infarction in the absence of treatment, Arch Intern Med, 162, 2405, 10.1001/archinte.162.21.2405 Smith, 2002, AHA conference proceedings. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. American Heart Association, Circulation, 101, 111, 10.1161/01.CIR.101.1.111 De Backer, 2004, European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice, Eur Heart J, 24, 1601, 10.1016/S0195-668X(03)00347-6 Gibbons, 2003, J Am Coll Cardiol, 41, 159, 10.1016/S0735-1097(02)02848-6 De Velasco, 1997, Prevención secundaria del infarto de miocardio en España. El estudio PREVESE, Rev Esp Cardiol, 50, 406, 10.1016/S0300-8932(97)73242-1 De Velasco, 2004, Programa de intervención para mejorar la prevención secundaria del infarto de miocardio. Resultados del studio PRESENTE (Prevención Secundaria Temprana), Rev Esp Cardiol, 57, 146, 10.1157/13057265 De Velasco, 2002, Nuevos datos de prevención secundaria en España. Resultados del estudio PREVESE II, Rev Esp Cardiol, 55, 801, 10.1016/S0300-8932(02)76708-0 Leal Hernández, 2004, Paciente polimedicado ¿Conoce la posología de la medicación? ¿Afirma tomarla correctamente?, Aten Primaria, 33, 451, 10.1157/13061580 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, 1615, 10.1001/jama.279.20.1615 Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301 Brenner, 2002, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Hennekens, 2004, Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses, Arch Intern Med, 164, 40, 10.1001/archinte.164.1.40 Hippisley-Cox, 2005, Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis, BMJ, 30, 1059, 10.1136/bmj.330.7499.1059 Fox, 2003, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study), Lancet, 362, 782, 10.1016/S0140-6736(03)14286-9 Nissen, 2004, Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial, JAMA, 292, 2217, 10.1001/jama.292.18.2217 2002, Clinical practice recommendations 2002, Diabetes Care, 25, S1